• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Thank God the GROW calls are FINISHED

Anonymous

Guest
What a waste of time. I will miss hearing people tell "success stories" that take 17 minutes and include so many worthless details they don't even remember the point of their own stories. Not to mention, the talking in circles to avoid the real problems. Yeah we're sales people we get the whole refocus/redirect thing. In their defense I know they were trying to maintain morale, stay positive and keep the CA pep rally going.